Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 6/20 | 0.66 |
| ▸ | RAD52 | P43351 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.61 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.61 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30253677 | 1.00 | POLB (0.66) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL7880366 | 0.90 | POLB (0.78) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL15867122 | 0.89 | POLB (0.68) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL18631798 | 0.85 | POLB (0.49) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL18655368 | 0.83 | POLB (0.48) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL28158394 | 0.83 | POLB (0.68) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL7869214 | 0.82 | POLB (0.79) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL5578493 | 0.82 | POLB (0.79) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL6033155 | 0.81 | POLB (0.77) | POLBRAD52RAB9AKDM4EMITF | |
| SCHEMBL13856923 | 0.81 | POLB (0.77) | POLBRAD52RAB9AKDM4EMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181185-A1 | PAYLOAD AND LINKER DESIGNS FOR PLATINUM-ACRIDINE ANTICANCER AGENTS AND METHODS THEREOF | WAKE FOREST UNIVERSITY | 2020-06-11 | — | — | US | disclosed |
| US-10377784-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | WAKE FOREST UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2019046278-A1 | PAYLOAD AND LINKER DESIGNS FOR PLATINUM-ACRIDINE ANTICANCER AGENTS AND METHODS THEREOF | WAKE FOREST UNIVERSITY (US) | 2019-03-07 | — | — | WO | disclosed |
| US-10023599-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | WAKE FOREST UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023599-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | WAKE FOREST UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-9765103-B2 | Cleavable conjugates of functionalized platinum-acridine and platinum-benzacridine agents and methods thereof | WAKE FOREST UNIVERSITY | 2017-09-19 | — | — | US | disclosed |
| US-20170210772-A1 | Cleavable Conjugates of Functionalized Platinum-Acridine and Platinum-Benzacridine Agents and Methods Thereof | WAKE FOREST UNIVERSITY | 2017-07-27 | — | — | US | disclosed |
| US-20170081351-A1 | Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20170081351-A1 | Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-9273080-B2 | Metal complexes | MEREK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-8906896-B2 | Platinum acridine anti-cancer compounds and methods thereof | WAKE FOREST UNIVERSITY | 2014-12-09 | — | — | US | disclosed |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | WAKE FOREST UNIVERSITY | 2014-07-10 | — | — | US | disclosed |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | WAKE FOREST UNIVERSITY | 2014-07-10 | — | — | US | disclosed |
| WO-2013033430-A1 | TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST SCHOOL OF MEDICINE (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033430-A1 | TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST SCHOOL OF MEDICINE (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120039800-A1 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof | WAKE FOREST UNIVERSITY | 2012-02-16 | — | — | US | disclosed |
| US-20120039800-A1 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof | WAKE FOREST UNIVERSITY | 2012-02-16 | — | — | US | disclosed |
| EP-2358203-A1 | PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | Wake Forest University (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010048499-A1 | PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST UNIVERSITY (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048499-A1 | PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF | WAKE FOREST UNIVERSITY (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039800-A1 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof | ACR, TP53, BAD | POLB 308/4885RAD52 128/4885RAB9A 996/4885 |
| US-10023599-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | ACR, TP53, MCL1 | POLB 308/4885RAD52 1051/4885RAB9A 1022/4885 |
| US-10377784-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | ACR, TP53, BAD | POLB 284/4885RAD52 973/4885RAB9A 1053/4885 |
| US-20200181185-A1 | PAYLOAD AND LINKER DESIGNS FOR PLATINUM-ACRIDINE ANTICANCER AGENTS AND METHODS THEREOF | ACR, PAICS, IDH1 | POLB 1338/4885RAD52 98/4885RAB9A 1297/4885 |
| US-20170081351-A1 | Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith | ACR, TP53, MCL1 | POLB 308/4885RAD52 1051/4885RAB9A 1022/4885 |
| US-20170210772-A1 | Cleavable Conjugates of Functionalized Platinum-Acridine and Platinum-Benzacridine Agents and Methods Thereof | CES2, CES1, BCHE | POLB 1309/4885RAD52 932/4885RAB9A 2573/4885 |
| US-20140193334-A1 | Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof | ERBB3, EGFR, ESR1 | POLB 4366/4885RAD52 2529/4885RAB9A 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.